CRSP - CRISPR Therapeutics AG
| Previous Close | 58.12 |
| Open | 58.27 |
| Bid | 55.25 x 800 |
| Ask | 55.70 x 1400 |
| Day's Range | 55.31 - 59.05 |
| 52 Week Range | 30.75 - 74.00 |
| Volume | 1,623,829 |
| Avg. Volume | 1,287,478 |
| Market Cap | 3.395B |
| Beta (5Y Monthly) | 3.23 |
| PE Ratio (TTM) | 47.69 |
| EPS (TTM) | 1.17 |
| Earnings Date | Feb 23, 2020 - Feb 27, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 75.96 |
- Yahoo Finance Video
Axsome Therapeutics jumps as migraine drug hits goals in late-stage trial
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.
- Benzinga
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
- Zacks
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $57.76 in the latest trading session, marking a +1.33% move from the prior day.
- GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
-Enrollment ongoing in clinical trials of CTX001™ for patients with severe hemoglobinopathies- -Enrollment ongoing in clinical trial of CTX110™, targeting CD19+.
- Investor's Business Daily
CRISPR Therapeutics Shows Market Leadership With Jump To 92 RS Rating
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. Can it continue?
- Zacks
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $54.33 in the latest trading session, marking a -0.93% move from the prior day.
- Zacks
Expand Your Portfolio with this First Profit Stock Screener
Expand Your Portfolio with this First Profit Stock Screener
- Zacks
CRISPR Therapeutics AG (CRSP) Stock Moves -0.9%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $51.95 in the latest trading session, marking a -0.9% move from the prior day.
- Zacks
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
- Zacks
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
- American City Business Journals
Acceleron stock soars on lung drug trial data
Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.
- American City Business Journals
European ruling threatens Broad's CRISPR gene-editing patents
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
- Zacks
SCANS: The FAANG of The Roaring 20s
A new acronym of equities that could define the next decade of investing.
- Zacks
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
The Zacks Analyst Blog Highlights: Sea Limited, CRISPR, Alibaba, Nvidia and Splunk
- GlobeNewswire
CRISPR Therapeutics to Present at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
- Investor's Business Daily
These Top Fund Managers Outperform With Stocks That Many Other Investors Avoid
If you look for mutual funds to invest in, 2019 was a blast. The S&P; 500's 2019 gain of 31.49% was the broad market's best since 2013's 32.39%.
- Zacks
CRISPR Therapeutics AG (CRSP) Gains As Market Dips: What You Should Know
CRISPR Therapeutics AG (CRSP) closed at $59.44 in the latest trading session, marking a +0.2% move from the prior day.
- Investor's Business Daily
Gene-Editing Stocks Dive As Creator Of CRISPR Babies Sent To Prison
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
- Investor's Business Daily
This CRISPR Stock Is A 2020 Top Pick — But Will Gene Editing Succeed?
Crispr Therapeutics is a top pick heading into 2020, an analyst said Friday, noting the biotech's CRISPR gene-editing drugs could soon boost shares. Crispr stock topped a profit-taking zone.
- Simply Wall St.
If You Had Bought CRISPR Therapeutics (NASDAQ:CRSP) Stock Three Years Ago, You Could Pocket A 212% Gain Today
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
- Zacks
What the Tech?
Let's REALLY dive deep into the abyss which can be tech. Associate Stock Strategist Dan Laboe, Zacks' resident Tech geek joins us.
- Insider Monkey
Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP) ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
